SCHEMBL6402174

SCHEMBL6402174

O=P(O)(O)c1ccc(O)cc1C(O)(O)CCc1ccc(O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.37
ESR2 Q92731 1/20 0.37
LTA4H P09960 1/20 0.36
CA2 P00918 1/20 0.34
NR1H3 Q13133 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP2C19 P33261 2/20 0.33
ESRRG P62508 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR3A P46098 1/20 0.33
BACE1 P56817 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
SLC28A3 Q9HAS3 2/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395047 0.92 IGF1R (0.37) ESR1ESR2LTA4HKDM4EALDH1A1
SCHEMBL6395042 0.88 ESR1 (0.37) ESR1ESR2LTA4HCA2KDM4E
SCHEMBL6398625 0.87 DRD2 (0.41) NR1H3TAAR1
SCHEMBL6402573 0.85 FDPS (0.40) ESR1ESR2BLMFDPSPTPN1
SCHEMBL6396954 0.80 IGF1R (0.37) ESR1ESR2LTA4HKDM4EALDH1A1
SCHEMBL6402094 0.80 MGLL (0.40) NR1H3TAAR1FDPS
SCHEMBL6403581 0.79 INPPL1 (0.37) ESR1ESR2LTA4HKMT2AMEN1
SCHEMBL6402166 0.79 ESR1 (0.34) ESR1ESR2LTA4HCA2NR1H3
SCHEMBL6403605 0.77 ESR1 (0.40) ESR1ESR2LTA4HCA2KDM4E
SCHEMBL6395037 0.76 ESR1 (0.34) ESR1ESR2LTA4HCA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885LTA4H 2051/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885LTA4H 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.